--- title: "The list of cooperative projects and long-term value in Jingtai's hands" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/32697956.md" description: "The core conclusion is: It has the potential for "high beta" returns!! Isn't this exactly what I want to buy? 😂 1. Table organization (in reverse chronological order, 2020-09 → 2025-08, total of 39 entries) #TradingTime Partner *(Assignee) Key Points of Transaction/Cooperation (Compressed from official announcements or news headlines) Related Technology/Project 1 2025-08-05 DoveTree Signed a "Letter of Intent for Cooperation, focusing on small molecules + antibody drugs..." datetime: "2025-08-07T06:49:05.000Z" locales: - [en](https://longbridge.com/en/topics/32697956.md) - [zh-CN](https://longbridge.com/zh-CN/topics/32697956.md) - [zh-HK](https://longbridge.com/zh-HK/topics/32697956.md) author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)" --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/32697956.md) | [繁體中文](https://longbridge.com/zh-HK/topics/32697956.md) # The list of cooperative projects and long-term value in Jingtai's hands > ### The core conclusion is: It has the potential for "high beta" returns!! Isn't this exactly what I want to buy? 😂 ### 1\. Table Summary (Reverse Chronological Order, 2020-09 → 2025-08, 39 Entries) # Transaction Time Partner \*(Assignee) Key Points (Compressed from Official Announcements or News Headlines) Technology/Project Involved 1 2025-08-05 **DoveTree** Signed a Letter of Intent to collaborate on small molecule + antibody drugs, integrating AI + robotics platforms Small molecules/antibodies, AI-Lab automation 2 2025-07-25 **Jingsaihang** PepiX peptide R&D platform collaborates with Jingsaihang to build a peptide-radionuclide drug pipeline Peptide-radionuclide conjugation 3 2025-06-29 **Pfizer** Expanded strategic collaboration: AI-driven drug and material simulation Molecular modeling platform 4 2025-04-01 Pais Shuanglin Bio AI-powered development of specialty novel peptides/blood products Plasma products and peptide drugs 5 2025-02-10 **Alternative Bio** → XtalPi Strategic investment and synergy to accelerate first-in-class drugs Innovative drug R&D 6 2025-01-09 **UCB** AI platform for macromolecular drug discovery licensing agreement **XtalFold™** 7 2024-10-10 **Janssen Biotech** AI platform for macromolecular drug discovery licensing agreement **XtalFold™** 8 2023-12-18 C&C Research Labs Joint research on STAT6-targeted therapies STAT6 project 9 2023-09-04 Parthenon Therapeutics AI-powered next-generation oncology drug "XupremAb®" XupremAb® platform 10 2023-08-21 CSPC Pharmaceutical Group Embedding AI decision-making in innovative drug R&D AI technology platform 11 2023-05-30 **Eli Lilly** AI + robotics assist "first-in-class" targets **ID4Inno™** platform 12 2023-03-15 **DeepTech** Building an AI4S intelligent, automated drug R&D ecosystem AI for Science computing 13 2022-12-19 **A\*STAR/EDDC** AI-powered non-small cell lung cancer project AI technology 14 2022-11-24 **CK Life Sciences (CKLS)** AI-driven novel paradigm for cancer vaccine R&D Cancer vaccine platform 15 2022-10-27 **Janssen Biotech** Inclusive Digital Drug Discovery (ID4) joint research **ID4 platform** 16 2022-09-29 Jikang Bio Joint research on GPCR-targeted antibody drugs GPCR antibodies 17 2022-07-18 Shuyan Tech Automated synthesis + AI for RNA-targeted small molecule drugs RNA-targeted drugs 18 2022-06-06 **Qilu Pharmaceutical** First-in-class small molecule drugs for high-difficulty oncology targets Oncology FIC 19 2022-04-26 **Livzon Pharmaceutical** AI-powered chronic disease small molecule innovation Chronic disease small molecules 20 2022-01-18 **Zhengda Tianqing** High-difficulty anti-cancer small molecule targets High-difficulty targets 21 2022-01-14 **Kinde Pharma** Joint research on novel ADCs Antibody-drug conjugates 22 2021-12-16 **Antengene** AI-accelerated pipeline development AI technology 23 2021-12-01 **B.A.I.** AI peptide/dermatology drug collaboration AI platform 24 2021-10-27 **Signet Therapeutics** Expanded AI drug discovery collaboration, focusing on new oncology targets sigx1094; ID4 25 2021-09-28 Acerand Therapeutics Physics-AI combined model for novel anti-cancer drugs Novel anti-cancer 26 2021-09-07 **Kintor Pharma** AI discovery of monoclonal antibody drugs AI technology 27 2021-08-31 **Geode Therapeutics** AI advances 2 immune pipelines (including XTC-002) Immune pipelines 28 2021-08-17 **Sedec Therapeutics** Innovative small molecule drug discovery for autoimmune diseases AI technology 29 2021-07-19 Zhongao Bio AI-designed protein drugs AI technology 30 2021-07-16 Jacobio Accelerating high-difficulty oncology small molecule FIC AI technology 31 2021-07-13 Qinhao Pharma Primitive innovative small molecule anti-cancer drugs AI technology 32 2021-07-12 Lingli Tech AI + DEL platform for RNA-targeted small molecules RNA-targeted platform 33 2021-06-22 **Kinde Pharma** AI-assisted ADC design AI technology 34 2021-04-08 **Signet Therapeutics** Progress in oncology projects sigx1094 and ID4 sigx1094; ID4 35 2021-03-25 Shanghai Qingao Pharma Launch of multiple AI-powered oncology pipelines **AI technology** 36 2021-02-03 **Singleron** AI + single-cell sequencing to explore oncology targets AI technology 37 2020-11-11 **Huadong Medicine** AI involvement in new oncology target drug R&D New oncology targets 38 2020-10-22 **3D Medicines** Joint development of next-generation cancer immunotherapy drugs AI technology 39 2020-09-08 **PhoreMost** AI challenge for "undruggable" oncology targets **ID4 platform** \* Note: The "Partner" column lists the counterparty name; the assignor is almost entirely XtalPi (or DeepTech), with a few exceptions (e.g., Alternative Bio investment). * * * ### 2\. Long-Term Business Value Assessment Dimension Observation Points Value Judgment **Partner Quality** Covers global pharma giants (Pfizer, Eli Lilly, Janssen, UCB), regional leaders (Qilu, Livzon, Zhengda Tianqing), and early-stage biotechs/research institutions ① **High credibility endorsement**: Repeat contracts with multinational pharma (Pfizer, Janssen twice) indicate sustained platform recognition. ② **Pipeline diversification**: Multi-region, multi-target distribution reduces single-project failure risk. **Contract Model** Licensing (XtalFold™, ID4Inno™), joint R&D, technical services, and equity investment ① **Licensing**: Sustainable milestone + royalties; high potential cash flow if products launch. ② **Joint R&D**: XtalPi handles early research; if successful, shares clinical-stage benefits. ③ **Equity + Tech**: e.g., Alternative Bio, capital gains while binding clients. **Technology Flywheel** Robotic automation, AI4S computing, ID4/ID4Inno platforms, XtalFold™ protein folding Each deal generates **high-quality structure-activity-process data** → trains models → improves success rates; positive feedback aligns with "large model + automation" network effects. **Disease/Target Distribution** Oncology (\>60%), autoimmune, infectious diseases, vaccines, rare diseases Oncology has high commercial potential; RNA, GPCR, ADC, and radiolabeled peptides represent next-wave opportunities. **Timeline** 2020 ramp-up → 2022 breakout → 2023-2025 high-quality pharma collaborations Growth in quantity/quality reflects platform maturity; **next 3-5 years** critical for IND/clinical validation—1-2 successes could drive valuation leaps. **Risks** Low clinical success rates; early-stage collaborations dominate; cash flow relies on service revenue ① Core model stagnation or competitor (Insilico, Recursion) disruption may erode differentiation. ② Pharma in-house AI capabilities could reduce outsourcing. #### Key Opportunities / High-Value Collaborations Collaboration Highlights Value Inference **Pfizer (2025)** AI + materials science simulation, expanded scope If integrated company-wide → service fees + milestones could exceed $50M **Eli Lilly (2023)** AI + robotics for "first-in-class" targets Robotics-computing integration is XtalPi’s edge; clinical entry would be landmark **Janssen Dual Deals (2021, 2022)** XtalFold™ macromolecular folding licenses Recurring fees prove B2B reusability; long-term royalties if successful **UCB (2025)** Folding platform licensed for antibodies/macromolecules First major European pharma adoption → new regional market **Qilu Pharma (2022)** High-difficulty FIC target collaboration If China’s first-in-class drug emerges, XtalPi shares milestones/sales, proving local monetization * * * ### 3\. Summary **Sustainable Business Model**: "AI + automation" delivers algorithms, platforms, data, and early-stage molecules via service fees, milestones, royalties, and equity—forming a **"low cash burn + high backend leverage"** combo. **Long-Term Catalysts**: 2026-2028 is the window for multiple pipelines entering Phase I/II. Any success (especially with Pfizer/Lilly/Janssen) would boost valuation and bargaining power. **Key Metrics**: ① 1-2 IND submissions annually; ② Shorter discovery-validation cycles; ③ \>40% CAGR in commercial revenue (non-funding). > $XTALPI(02228.HK) **Overall Assessment**: Validated by pharma giants, diversified pipelines, and data flywheel, XtalPi (and partner DeepTech) offers "high beta" potential; risks center on clinical externalities and competition—requiring relentless algorithm/automation innovation. ### Related Stocks - [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md) ## Comments (11) - **收获总是在秋天 · 2025-08-07T14:02:19.000Z**: Could you please advise, boss, on the valuation model for crystalline state, or are there any comparable companies for reference? - **老板的老板 AI Exec** (2025-08-07T14:35:40.000Z): There doesn't seem to be any at the moment. The only one in the world. - **韭菜想赚钱 · 2025-08-07T08:14:21.000Z**: Thanks for sharing, boss! - **Patience is key in life · 2025-08-07T07:56:49.000Z**: Thanks for the massage💆 - **天台排队叫号中 · 2025-08-07T07:49:32.000Z**: Thanks boss, I sold too early last time, this time I'll be patient and wait for an entry opportunity. - **江汉南京 · 2025-08-07T07:27:04.000Z**: Thank you, boss. Wishing you favorable weather, peace, and good health for your family. - **John_Tang · 2025-08-07T07:13:26.000Z**: Thank you 🙏 - **Ω骑墙派 · 2025-08-07T07:03:19.000Z · 👍 1**: Thank you, boss! - **俗世文人 · 2025-08-07T06:52:39.000Z**: Dear boss, is there any follow-up progress on the cosmetics and desert planting projects? - **老板的老板 AI Exec** (2025-08-07T06:54:40.000Z): It should all continue. - **周树人的交易员 · 2025-08-07T06:52:12.000Z · 👍 1**: Thanks for sharing 🙏🏻